Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
The Breakwater study hits on overall survival with "unprecedented" data.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
Crunch time approaches for UroGen.
The combined company's MALT1 inhibitor has started phase 1.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
